A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.

  title={A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.},
  author={John Seth Markowitz and C. Lindsay DeVane and Linda K Pestreich and Kennerly Sexton Patrick and Rafael Muniz},
  journal={Journal of child and adolescent psychopharmacology},
  volume={16 6},
dl-Methylphenidate (MPH) has been widely used to treat attention-deficit/hyperactivity disorder (ADHD) for the last half century. It had been exclusively available in the racemic form, i.e., a 50:50 mixture of d- and l-isomers. However, a single enantiomer formulation, d-MPH (dexmethylphenidate), became available for general clinical use in 2002. For this reason, the intrinsic pharmacological differences in the effects of d- and l-MPH have recently come under intense investigation. The primary… 

Figures and Tables from this paper

Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?

Data from in vitro, animal, and human studies support the premise that the d-enantiomer of MPH mediates the neurophysiological actions of MPH and therefore likely mediates its clinical efficacy.

Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic–pharmacodynamic relationships

Sarizotan may have potential anti-ADHD effects at low doses free of the previously reported side-effects and a classical pharmacokinetic–pharmacodynamic relationship based on free brain concentrations seems to be less appropriate than target engagement pharmacodynamic readouts.

The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.

d-threo-(R,R)-MPH appears to act as a selective 5-HT(1A) receptor agonist in vitro, and it is speculated that the activation of 5- HT(1a) receptor might play a partial role in d-THreo-MPH mediated dopamine (DA) release in the brain.

Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.

  • M. PattC. Solbach H. Machulla
  • Chemistry, Biology
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2007
The application of the sodium salt of d-threo-N-NPS-ritalinic acid as precursor resulted in higher radiochemical yields than the use of the free acid under basic conditions, and the purification process could be simplified (omission of one solid phase extraction step), resulting in an easily automated process for the production of the tracer.

New Formulations of Stimulants: An Update for Clinicians.

Clinical knowledge about differences in MPH and AMP pharmacodynamics, pharmacokinetics, and metabolism can be utilized to personalize treatment and optimize response to ADHD treatment.

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

The reported new compounds act on hMATs as well as the structures of the transporters complexed with diverse ligands by either experiment or computational modeling have shed light on the poly-pharmacology, multimodal and allosteric regulation of the drugs totransporters.

The discriminative stimulus properties of methylphenidate in C57BL/6J mice

Preclinical findings provide insight into relative potency, and by extension, efficacy of dl-MPH versus d- MPH doses, as well as the threshold doses needed to produce stimulatory effects of motor activity in B6 mice.

Riederer In-vitro study methodologies to investigate genetic aspects and effects of drugs used in Attention-deficit Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children and adolescents, with up to 5 % affected worldwide. Twin and family studies on ADHD show

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

d-MPH-ER and d,l-MPh-ER improved ADHD symptoms and were well tolerated and all active treatments provided a significant benefit over placebo at most time points to 12 hours post-dosing.



D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits.

Rats and rabbits dosed with D,L-MPH exhibited significantly greater incidence of maternal clinical observations at twice the dose of D- MPH, and both compounds were not teratogenic in rats and rabbits at higher exposure levels compared to humans.

New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder

The newly approved resolved enantiomer product d-MPH is now available in an IR formulation, and when administered at one-half the dose to that of the racemate, is purported to produce a longer duration of clinical effect, despite essentially identical pharmacokinetics.

Pharmacology of the enantiomers of threo-methylphenidate.

Results suggest that synaptic inhibition of catecholaminergic uptake by d-threo-MPH may be involved fundamentally in behavioral and pressor effects of the racemic drug.

Synthesis and pharmacology of hydroxylated metabolites of methylphenidate.

Findings suggest that metabolite 5a may play a role in the pharmacology of 1a, and the intracerebroventricular administration of acids 2a, 2b, 6 a, and 6b all produced a small increase in locomotor activity relative to their methyl esters which was not appreciably affected by stereochemistry or para-hydroxylation.

Enantioselective pharmacokinetics and pharmacodynamics of dl‐thero‐mcthylphenidate in children with attention deficit hyperactivity disorder

The computer tests revealed a drug‐induced improvement in sustained attention that was entirely attributable to the d‐enantiomer, and there was no evidence to suggest that the effectiveness of d‐methylphenidate was in any way compromised by the presence of its antipode.

Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans

It was found that chewing the slow release formulation led to a pharmacokinetic profile very similar to that of MPH-IR, suggesting that MPH-SR should not be prescribed for children who chew tablets.

Binding of bromine-substituted analogs of methylphenidate to monoamine transporters.

Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration

Results suggest that, in animal models, l‐threo‐MP or its metabolite(s) is (are) absorbed from the gastrointestinal tract and enters the brain after oral administration, but that l‐thano‐ MP may not be pharmacologically active.

Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics

Women reported a significantly greater stimulant effect than men when questioned “Do you feel any drug effect?” (P<0.05), in spite of lower mean plasma d‐MPH area under the response–time curves in women.

Dose‐Proportional and Stereospecific Pharmacokinetics of Methylphenidate Delivered Using an Osmotic, Controlled‐Release Oral Delivery System

Plasma concentrations of l‐methylphenidate were 40‐fold lower than those of d‐ methylphenidate, whereas plasma concentrations of d-α‐phenyl‐2‐piperidine acetic acid and l‐PPA, the major metabolite of methyl phenidate, were comparable, indicating that methylphenidates metabolism was not affected by increasing dose.